Extending the Impact of ADCs

Beyond broad internal development of our antibody-drug conjugate (ADC) technology, we have entered into collaborations with a number of industry-leading biotechnology and pharmaceutical companies. These licensing activities extend the reach of our technology as collaborators investigate numerous targets in many therapeutic areas.

In addition to extending the reach of our technology into additional programs, our ADC technology licensing agreements provide us with future pipeline opportunities through co-development or opt-in rights to new ADC product candidates.

We have two types of ongoing ADC collaborations:

Under our ADC license agreements with AbbVie, Astellas, Bayer, Genentech, GlaxoSmithKline, and Progenics, we are entitled to receive upfront payments, milestones and royalties on net sales of any resulting ADC products. Our licensees are responsible for all development, manufacturing and commercialization activities under these collaborations.

Our ADC co-development agreements with Astellas and Genmab provide Seattle Genetics with opportunities to supplement our internal pipeline through opt-in rights to 50:50 co-development and profit-sharing for ADC product candidates. Under these collaborations, we are co-developing enfortumab vedotin with Astellas and tisotumab vedotin with Genmab.

ADC Collaborator Pipeline

Polivy(TM) (polatuzumab vedotin-piiq) (anti-CD79b ADC)

Relapsed/refractory diffuse large B-cell lymphoma

Approved by FDA

Anti-S. aureus TAC (RG7861)


Telisotuzumab vedotin (ABBV-399)



Solid tumors


DLBCL (co-developed with Cytomx)

Belantamab mafodotin (anti-BCMA ADC; GSK2857916)

Multiple myeloma (BTD and PRIME)


Prostate cancer

Enapotamab vedotin (HuMax-AXL-ADC)

Solid tumors